Abstract
Data defining the clinical course of COVID19 infection in HSCT recipients are limited. We assessed the impact of COVID19 on paediatric HSCT recipients in the UK between February and June 2020. Nine patients developed COVID 19 proven infection at a median time of 62 days post-transplant. Presenting symptoms were mostly fevers and cough. One case had a severe course, requiring non-invasive ventilation and receiving dexamethasone, tocilizumab, remdesivir. No patients died from COVID19. Two patients developed significant complications following COVID19 disease. Our data describe a relative mild infection course in HSCT recipients but highlight potential infectious triggered complications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
